The impact of rheumatoid arthritis on the economic situation of Polish households
More details
Hide details
Submission date: 2013-02-26
Final revision date: 2013-07-04
Acceptance date: 2013-08-02
Online publication date: 2013-10-31
Publication date: 2013-10-30
Reumatologia 2013;51(5):348–354
Objectives: Rheumatoid arthritis (RA) is a chronic disease which causes patient disability and affects the situation of the patient’s household. On the one hand, the disease is associated with treatment costs and the need to adapt the patient’s environment but on the other hand it limits the employment options available to the patients and their families. The purpose of this work is to evaluate the cost of rheumatoid arthritis and to verify whether the disease has an impact on the economic situation of households.
Material and methods: The survey study was conducted by professional surveyors between November 2009 and March 2010. The study included 1,000 respondents with diagnosed rheumatoid arthritis (RA) from the patient pool of 50 randomly selected Polish rheumatology outpatient clinics.
Results: The obtained results related to household budgets were compared with data available from the Central Statistical Office (GUS) for 2009 (desk research). The comparison indicates that RA actually affects the household budgets. RA patient households have reduced income levels as compared to the national average and their expenditures on healthcare per person are almost twice as high. While the average household expenditures related to healthcare amount to PLN 47.90, the expenditures of RA patient households reach PLN 93.37. Financial issues were reported by 49% of RA patient households as compared to 20% of households in general (acc. to GUS). Also, the assistance provided by third parties significantly affects the cost level.
Conclusions: The disease significantly limits earning options available to the patients and their families and at the same time it increases the costs related to treatment and patient disability. In order to reduce the socio-economic impact of the disease it is necessary to ensure early diagnosis and early onset of appropriate treatment.
Kobelt G, Kasteng F. Access to innovative treatments In rheumatoid arthritis In Europe. October 2009; A report prepared for The European Federation of Pharmaceutical Industry Associations (EFPIA).
Raport z badania w Zakładzie Epidemiologii Chorób Reumatycznych „Nasze zdrowie, nasze dolegliwości”. Warszawa 2002. http://www.pzh.gov.pl/page/fil....
Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull WHO 2003; 81: 646-656.
Stan zdrowia ludności w 2009 r. GUS, Warszawa 2011.
Orzeczenia lekarzy orzeczników ZUS o niezdolności do pracy wydane w 2010 roku. Zakład Ubezpieczeń Społecznych, Departament Statystyki i Prognoz Aktuarialnych. Warszawa 2011.
Wydatki na świadczenia z ubezpieczeń społecznych związane z niezdolnością do pracy w 2010 roku. Zakład Ubezpieczeń Społecznych, Departament Statystyki i Prognoz Aktuarialnych. Warszawa 2011.
Verstappen SM, Jacobs JW, Kruize AA, et al. Trends in economic consequences of rheumatoid arthritis over two subsequent years. Rheumatology 2007; 46: 968-974.
Boonen A, van der Heijde D, Landewé R, et al. Costs of ankylosing spondylitis in three European countries: the patient’s perspective. Ann Rheum Dis 2003; 62: 741-747.
Ólafsson S. Social and personal costs of arthritis and rheumatic diseases. An exploratory eurvey. TemaNord 2008; 583.
Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-145.
Rupiński R, Filipowicz-Sosnowska A. Aktywność choroby a niepełnosprawność u chorych na reumatoidalne zapalenie stawów. Reumatologia 2005; 43: 129-137.
Budżety gospodarstw domowych w 2009 r. GUS, Warszawa 2010.
Jacobson LT, Lindroth Y, Marsai I, et al. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community?derived population in Malmö, Sweden. Scand J Rheum 2007; 36: 179-183.
Hülsemann JL, Mittendorf T, Merkesdal S, et al. Direct costs related to rheumatoid arthritis: the patient perspective. Ann Rheum Dis 2005; 64: 1456-1461.
Huscher D, Merkesdal S, Thiele K, et al., for the German Collaborative Arthritis Centres. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006; 65: 1175-1183.
van den Berg B, Al M, Brouwer W, et al. Economic valuation of informal care: The conjoint measurement method applied to informal caregiving. Soc Sci Med 2005; 61: 1342-1355.
Verstappen SM, Boonen A, Verkleij H, et al., on behalf of the Utrecht Rheumatoid Arthritis Cohort Study Group (SRU). Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis 2005; 64: 1754-1760.
Mały rocznik statystyczny 2010. GUS, Warszawa.
Verstappen SM, Verkleij H, Bijlsma JW, et al., on behalf of the Utrecht Rheumatoid Arthritis Cohort Study group (SRU). Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 2004; 63: 817-824.
Westhovens R, Boonen A, Verbruggen L, et al. Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 2005; 24: 615-619.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.